BMY Q1 2023 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q1 2023 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$11.3B-2.7% YoY

Gross Profit

$6.5B57.5% margin

Operating Income

$2.5B21.6% margin

Net Income

$2.3B20.0% margin

EPS (Diluted)

$1.07

QoQ Revenue Growth

-0.6%

Cash Flow

Operating Cash Flow

$3.0B

Free Cash Flow

$2.7B

Stock-Based Comp.

$122M

Balance Sheet

Total Assets

$94.3B

Total Liabilities

$62.4B

Stockholders' Equity

$31.8B

Cash & Equivalents

$9.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.3B	$11.6B	-2.7%
Gross Profit	$6.5B	$6.8B	-3.6%
Operating Income	$2.5B	$2.7B	-9.5%
Net Income	$2.3B	$1.3B	+77.0%

Revenue Segments

Eliquis

$3.4B30%

Opdivo

$2.2B20%

Revlimid

$1.8B16%

Pomalyst/Imnovid

$832M7%

Orencia

$764M7%

Yervoy

$508M5%

Mature Products And All Other

$467M4%

Sprycel

$429M4%

Abraxane

$239M2%

Reblozyl

$206M2%

Abecma

$147M1%

Opdualag

$117M1%

Zeposia

$78M1%

Breyanzi

$71M1%

Camzyos

$29M0%

Sotyktu

$16M0%

Geographic Segments

UNITED STATES

$8.0B71%

Rest Of World

$3.1B28%

Other Region

$155M1%